A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Egile nagusia: | Karim, Azrin |
---|---|
Beste egile batzuk: | Islam, Farzana |
Formatua: | Project report |
Hizkuntza: | English |
Argitaratua: |
Brac University
2024
|
Gaiak: | |
Sarrera elektronikoa: | http://hdl.handle.net/10361/24372 |
Antzeko izenburuak
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
nork: Islam, Saidul
Argitaratua: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
nork: Ahmed, Nafisa
Argitaratua: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
nork: Meem, Manila
Argitaratua: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
nork: Hossain, Sadman Sanjid
Argitaratua: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
nork: Jahan, Nusrat
Argitaratua: (2024)